

Supplementary Table 2. Baseline characteristics of the study population according to a mean glucose of 135 mg/dL during the first 3 months of continuous glucose monitoring wear

Characteristic	Mean glucose \leq 135 mg/dL ($n=42$)	Mean glucose $>$ 135 mg/dL ($n=135$)	<i>P</i> value
Age, yr	39.1 \pm 12.5	46.4 \pm 15.8	0.003
Sex			0.013
Male	12 (28.6)	66 (50.8)	
Female	30 (71.4)	64 (49.2)	
Duration of diabetes, yr	10.6 \pm 10.9	11.5 \pm 9.4	0.612
BMI, kg/m ²	21.8 \pm 3.1	23.2 \pm 3.1	0.017
SBP, mm Hg	116.0 \pm 14.1	118.4 \pm 15.1	0.366
DBP, mm Hg	68.3 \pm 12.1	67.0 \pm 11.1	0.523
Laboratory-HbA1c, %	6.4 \pm 1.0	7.7 \pm 1.2	$<$ 0.001
Laboratory-HbA1c, mmol/mol	57 \pm 11	61 \pm 13	
Total cholesterol, mg/dL	171.4 \pm 32.0	162.1 \pm 39.8	0.194
HDL-C, mg/dL	79.7 \pm 19.7	64.8 \pm 16.5	$<$ 0.001
LDL-C, mg/dL	93.5 \pm 28.0	94.1 \pm 36.7	0.931
Triglycerides, mg/dL	57.0 (47.0–95.5)	72.0 (57.0–97.8)	0.018
eGFR, mL/min/1.73 m ²	107.1 \pm 19.4	98.8 \pm 21.1	0.036
Hemoglobin, g/dL	12.9 \pm 2.2	13.4 \pm 1.8	0.389
C-peptide, ng/mL	0.21 (0.02–0.80)	0.02 (0.02–0.25)	0.030
Insulin delivery method			0.406
MDI	39 (92.9)	125 (96.2)	
Insulin pump	3 (7.1)	5 (3.8)	
Total daily insulin dose, IU	34.9 \pm 16.3	42.7 \pm 22.1	0.036
Basal dose	13.6 \pm 7.6	18.4 \pm 10.4	0.006
Meal dose	20.8 \pm 10.4	24.5 \pm 13.7	0.108
Use of antidiabetic agents ^a	1 (2.4)	1 (0.6)	1.000

Values are presented as mean \pm standard deviation, number (%), or median (interquartile range).

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; MDI, multiple daily insulin.

^aOnly two people used antidiabetic agents. One in the mean glucose \leq 135 mg/dL group used metformin, and one in the mean glucose $>$ 135 mg/dL group used sodium glucose co-transporter 2 inhibitor.